Our Focus

Advancing Medicines for Hormone Driven Cancers

Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers.

 

Apristor for PR+ Cancers

Apristor is an investigational medicine for breast, ovarian, and endometrial cancers. These cancers are progesterone-dependent and Apristor functions by blocking the progesterone receptor (PR).

 

Our Values

iconfinder_rocket_startup_shuttle_galaxy_launch_spaceship_space_1079598.png
iconfinder_globe_network_earth_planet_communication_web_worldwide_1079608 (1).png
iconfinder_businessman_ways_direction_choice_question_search_alternative_1079672.png
iconfinder_businessmen_gears_idea_creative_organization_teamwork_partnership_1076682.png

Greatness

RESPECT

INTEGRITY

TEAMWORK

 
latest news
 
events
 

Cancer Progress
May 7-8
New York, NY

American Society of Clinical Oncology (ASCO)
May 31-June 4
Chicago, IL